^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1)

    i
    Other names: EEF1A1, Eukaryotic Translation Elongation Factor 1 Alpha 1, Leukocyte Receptor Cluster (LRC) Member 7, Leukocyte Receptor Cluster Member 7, Eukaryotic Elongation Factor 1 A-1, Elongation Factor 1-Alpha 1, Elongation Factor Tu, EF-1-Alpha-1, EEF1A-1, EEF1A, LENG7, EF-Tu, EF1A, Eukaryotic Translation Elongation Factor 1 Alpha 1-Like 14, Glucocorticoid Receptor AF-1 Specific Elongation Factor, Translation Elongation Factor 1 Alpha 1-Like 14, Epididymis Secretory Sperm Binding Protein, Elongation Factor 1 Alpha Subunit, Prostate Tumor-Inducing Protein 1, Cervical Cancer Suppressor 3, CTCL Tumor Antigen, EF1a-Like Protein, GRAF-1EF, CCS-3, EE1A1, EEF-1, CCS3, PTI1
    23d
    Plant-derived nanovesicles from Ginkgo biloba seeds mitigate LPS-induced endothelial dysfunction and promote vascular homeostasis. (PubMed, Front Bioeng Biotechnol)
    Ginkgo seed-derived PDNVs exhibit vascular-protective and anti-inflammatory properties, supporting their potential as safe, multifunctional agents for endothelial modulation. Further studies are warranted to explore their therapeutic applications in vascular biology.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • IL1B (Interleukin 1, beta) • NOS3 (Nitric oxide synthase 3) • VCAM1 (Vascular Cell Adhesion Molecule 1) • CAT (Catalase) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • OCLN (Occludin)
    27d
    Integrated RNA-seq and RT-qPCR Workflow Identifies Non-IGH Fusion Transcripts as Individualized Molecular Markers for Monitoring Multiple Myeloma. (PubMed, Biomedicines)
    These findings suggest that individualized fusion transcripts serve as robust molecular markers for MRD surveillance. The proposed RNA-seq-RT-qPCR pipeline offers a clinically practical strategy to enhance precision diagnosis and personalized treatment in MM.
    Journal
    |
    IGH (Immunoglobulin Heavy Locus) • DDX5 (DEAD-Box Helicase 5) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)
    1m
    Identification of EEF1A1 as a therapeutic target in TNBC: Anticancer action of a novel Penicillide-derived inhibitor through ribosomal protein regulation. (PubMed, Bioorg Chem)
    Functional validation using actinomycin D and cycloheximide treatments demonstrated that compound 2 suppresses RPL27A and RPLP0 expression at the translational level, thereby inhibiting tumor cell invasion and migration and exerting robust antitumor effects. Collectively, these findings provide novel insights into the anticancer mechanisms of EEF1A1-targeting agents and highlight EEF1A1 as a promising therapeutic target for the treatment of TNBC.
    Journal
    |
    EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • RPL27A (Ribosomal Protein L27a)
    |
    dactinomycin
    2ms
    Loss of UFL1 confers enzalutamide resistance of prostate tumors by regulating METTL16-mediated m6A modification of EEF1A1 mRNA. (PubMed, Int J Biol Sci)
    Additionally, METTL16-mediated m6A modification of EEF1A1 mRNA activates the m6A-IGF2BP1 axis, resulting in increased EEF1A1 protein levels and enhanced resistance to ENZ-induced apoptosis. These findings uncover a novel UFL1-METTL16-EEF1A1 signaling pathway that drives ENZ resistance, suggesting that targeting this cascade may offer a promising therapeutic strategy for overcoming ENZ resistance in prostate cancer.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • METTL16 (Methyltransferase 16, RNA N6-Adenosine)
    |
    Xtandi (enzalutamide)
    2ms
    Fine-Tuning Side Chain Substitutions: Impacts on the Lipophilicity-Solubility-Permeability Interplay in Macrocyclic Peptides. (PubMed, Mar Drugs)
    These insights emphasize the need to simultaneously preserve both target engagement and optimal permeability when modifying side chains in cell-permeable macrocyclic peptides, positioning compound 17 as a robust scaffold for future lead optimization. This work furnishes a blueprint for balancing drug-like properties with therapeutic potency in macrocyclic therapeutics.
    Journal
    |
    EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1)
    2ms
    Discovery of a Covalent Small-Molecule eEF1A1 Inhibitor via Structure-Based Virtual Screening. (PubMed, J Chem Inf Model)
    Finally, MD simulations and pair-interaction energy analyses highlighted Lys84, Arg218, and Glu230 of eEF1A1 as key residues for driving its binding interactions to AKOS-04. These results reveal that AKOS-04, screened by SBVS against C234 of eEF1A1, represents a promising lead for eEF1A1-targeted pancreatic cancer therapy, highlighting the power of computational approaches in covalent drug discovery.
    Journal
    |
    EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1)
    4ms
    Integrated Bioinformatics Analysis of Differentially Expressed RNA-Binding Proteins in Human Gliomas. (PubMed, Cell Mol Neurobiol)
    Further, RBPs like RPS8, RPL5, RPS3A, EEF1A1, and EIF4E1B were found to be strongly correlated with patients' overall survival. Taken together, our analyses identified several candidate RBPs which might serve as potential targets for oncological measures against gliomas.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • RPS6 (Ribosomal Protein S6) • YBX1 (Y-Box Binding Protein 1) • CPEB1 (Cytoplasmic Polyadenylation Element Binding Protein 1) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • RPL5 (Ribosomal Protein L5) • SMAD7 (SMAD Family Member 7) • PABPC1 (Poly(A) Binding Protein Cytoplasmic 1)
    7ms
    Whole transcriptome analysis identifies ALB-EEF1A1 fusion as a novel biomarker in metastatic colorectal cancer. (PubMed, Cancer Pathog Ther)
    ALB-EEF1A1 may play a pivotal role in the metastatic transformation of primary CRC and significantly increase the risk of death. The identified ALB-EEF1A1 fusion transcripts are promising novel molecular targets that may serve as prognostic and diagnostic biomarkers and treatment targets for mCRC in the future.
    Journal
    |
    IL17A (Interleukin 17A) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1)
    7ms
    An inhibitor of UHM splicing factors exerts anti-leukemic activity by altering cell cycle progression and reducing lysosome acidification. (PubMed, Cell Signal)
    RNA-seq analysis additionally uncovered that SF-153 impaired lysosome acidification and inhibited autophagy to enhance the anti-leukemic activities. Taken together, our study characterized the multimodal mechanisms of inhibition by SF-153 in leukemia cells and laid the foundation for studying selective UHM inhibitors in future.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • MCM7 (Minichromosome Maintenance Complex Component 7)
    7ms
    Deep learning-based feature discovery for decoding phenotypic plasticity in pediatric high-grade gliomas single-cell transcriptomics. (PubMed, Comput Biol Med)
    By addressing underlying patterning processes and plasticity networks as therapeutic vulnerabilities, our findings provide precision medicine strategies aimed at modulating glioma cell fates and overcoming therapeutic resistance. We suggest transition therapy toward neuronal-like lineage differentiation as a potential precision therapy to help stabilize pHGG plasticity and aggressivity.
    Journal
    |
    NOTCH2 (Notch 2) • IGF2 (Insulin-like growth factor 2) • MEIS1 (Meis Homeobox 1) • CXXC5 (CXXC Finger Protein 5) • GATA1 (GATA Binding Protein 1) • ANXA6 (Annexin A6) • DKK3 (Dickkopf WNT Signaling Pathway Inhibitor 3) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • H3-3A (H3.3 Histone A) • GFAP (Glial Fibrillary Acidic Protein) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)
    |
    IDH wild-type
    7ms
    Targeting Eukaryotic Elongation Factor 1A: How Small-Molecule Inhibitors Suppress Tumor Growth via Diverse Pathways. (PubMed, Int J Mol Sci)
    Accordingly, the present work aims to examine their multifaceted modes of action more than just blocking protein synthesis. By unveiling these insights, our deepened knowledge of these eEF1A-binding inhibitors will inform the development of future eEF1A-targeted drugs for cancer treatment.
    Review • Journal
    |
    EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1)
    8ms
    Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in World Trade Center first responders. (PubMed, medRxiv)
    Comparison with unexposed controls demonstrated higher CHIP prevalence in WTC responders, particularly in those 55 or younger. Study highlights the potential utility of deep sequencing for CHIP detection with clinical, laboratory and exposure data to develop personalized risk-adapted screening programs for cancer and other CHIP-related conditions in individuals exposed to airborne carcinogens.
    Journal
    |
    DNMT3A (DNA methyltransferase 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1)
    |
    TET2 mutation